SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001420720-24-000008
Filing Date
2024-02-21
Accepted
2024-02-21 16:55:17
Documents
16
Period of Report
2024-02-15
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ibio-20240215x8k.htm   iXBRL 8-K 36978
2 EX-16.1 ibio-20240215xex16d1.htm EX-16.1 3497
  Complete submission text file 0001420720-24-000008.txt   164890

Data Files

Seq Description Document Type Size
3 EX-101.SCH ibio-20240215.xsd EX-101.SCH 4159
4 EX-101.DEF ibio-20240215_def.xml EX-101.DEF 3258
5 EX-101.LAB ibio-20240215_lab.xml EX-101.LAB 13975
6 EX-101.PRE ibio-20240215_pre.xml EX-101.PRE 10318
17 EXTRACTED XBRL INSTANCE DOCUMENT ibio-20240215x8k_htm.xml XML 4621
Mailing Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737
Business Address 600 MADISON AVENUE, SUITE 1601 NEW YORK NY 10022-1737 302 355-0650
iBio, Inc. (Filer) CIK: 0001420720 (see all company filings)

IRS No.: 262797813 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-35023 | Film No.: 24660613
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)